Administration of a single dose of these NPs (equivalent to 7.5 μg IL‐1α) i.p. on Day 1 of treatment to breast tumor (TUBO)‐bearing BALB/c mice caused significant tumor regression in 80% of treated mice.47 This evidence concerns the gene IL1A and neoplasm.